The use of probiotics (A) is claimed in the production of food or pharmaceutical compositions for preventing the onset of type II diabetes mellitus patients in patients having a predisposition towards this condition. Independent claims are included for: (a) (I)-containing food, food additive, 'alicament' or nutraceutical compositions for feeding obese (or potentially obese) subjects having a predisposition towards diabetes, to prevent the onset of type II diabetes； and (b) pharmaceutical compositions (not restricted to use as above) comprising one or more (I) and a pharmaceutical carrier.
